Prognosis of patients with heart failure can be independently predicted by urinary albumin to creatine ratio

August 13, 2009

The ratio of albumin to creatine in a person's urine is a powerful and independent predictor of prognosis of heart failure, concludes an Article in this week's issue of The Lancet. The Article is written by Professor John J V McMurray, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK, and colleagues.

Increased excretion of albumin in urine is an established risk factor for mortality, cardiovascular events, and kidney disease in the general population, and in patients with diabetes, high blood pressure, and other types of cardiovascular disease. In this study, the authors aimed to assess the prognostic value of a spot urinary albumin to creatine ratio (UACR) in patients with heart failure, using date from the Candersartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.

UACR was measuring at baseline and during follow up of 2310 patients. Patients were diagnosed as having very high albumin excretion (macroalbuminuria), less serious excretion (microalbuminuria) or normoalbuminuria. The researchers found 58% patients had normal UACR, 30% had microalbuminuria, and 11% had macroalbuminuria. The prevalence of increased UACR was similar in patients with reduced and preserved left ventricular ejection fractions (a measure of heart function). Patients with increased UACR were older, had more cardiovascular disease, worse kidney function, and a higher prevalence of diabetes than did those with normoalbuminuria.

However, a high prevalence of UACR was still noted in heart failure patients without diabetes, high blood pressure, or kidney disease. Higher UACR was associated with increased risk of death from cardiovascular causes or admission to hospital with worsening heart failure (the combined end point of the CHARM study), even after adjustment for kidney function, and diabetes/blood glucose status. Patients with microalbuminuria were 43% more likely to reach the combined end point than those with normal UACR; patients with macroalbuminuria were 75% more likely to reach the combined end point than those with normal UACR. When looking specifically at death due to cardiovascular causes, patients with microalbuminuria were 62% more likely to die from this cause than those with normal UACR, which rose to 76% more likely for patients with macroalbuminuria.

The authors conclude: "Increased UACR is a powerful and independent predictor of prognosis in heart failure...Because UACR is a simple, readily available clinical test that is widely used in primary and secondary care, it might be of value in risk stratification of patients with heart failure...Of Potential interest to physicians and patients is whether therapeutic reduction in albumin excretion, which did not occur with candesartan, might be useful in the prediction of improvement in clinical outcomes."

In an accompanying Comment, Dr Kevin Damman, Dr Hans L Hillege, and Dr Dirk J van Veldhuisen, Department of Cardiology, University Medical Center Groningen, Netherlands, say: "The role of albuminuria in heart failure deserves further attention and today's CHARM substudy offers a first glimpse into the relation between albuminuria and outcome, which seems in accordance with observations in the general population and other populations of patients...New prospective studies should answer the question of whether treatment of albuminuria can improve survival or at least, preserve kidney function in patients with heart failure."
Professor John J V McMurray, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK. T) +44 (0) 141 330 3479 E)

Dr Kevin Damman, Department of Cardiology, University Medical Center Groningen, Netherlands T) +31 503612345 E)

For full Article and Comment, see:


Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to